Fader, A. N., Roque, D. M., Siegel, E. R., Buza, N., Hui, P., Havrilesky, L. J., … Santin, A. D. (2020). Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis. In Gynecologic Oncology (Vol. 159, pp. 7–8). Elsevier BV. https://doi.org/10.1016/j.ygyno.2020.06.014

Fader, A. N., D. M. Roque, E. R. Siegel, N. Buza, P. Hui, L. J. Havrilesky, A. A. Secord, et al. “Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis.” In Gynecologic Oncology, 159:7–8. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.06.014.

Fader AN, Roque DM, Siegel ER, Buza N, Hui P, Havrilesky LJ, et al. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis. In: Gynecologic Oncology. Elsevier BV; 2020. p. 7–8.

Fader, A. N., et al. “Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis.” Gynecologic Oncology, vol. 159, Elsevier BV, 2020, pp. 7–8. Crossref, doi:10.1016/j.ygyno.2020.06.014.

Fader AN, Roque DM, Siegel ER, Buza N, Hui P, Havrilesky LJ, Secord AA, O’Malley DM, Backes FJ, Nevadunsky NS, Chambers SK, Edraki B, Celano P, Bellone S, Azodi M, Ratner ES, Litkouhi B, Silasi DA, Schwartz PE, Santin AD. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis. Gynecologic Oncology. Elsevier BV; 2020. p. 7–8.